Talazoparib pharma grade active pharmaceutical ingredient is supplied as the crystalline tosylate salt of the free base C19H14F2N6O (1207456-01-6; molecular mass 380.35 g/mol). The salt corresponds to the FDA-approved PARP1/2 inhibitor marketed as Talzenna capsules at 0.25 mg and 1.00 mg talazoparib per capsule. The substance is designated for development of oral solid dosage forms—tablet, capsule, and granule intermediates—as well as injectable presentations; however, the regulatory approved oral reference product is the capsule. The API is released as a white to off-white crystalline powder under a drug master file with specifications aligned to ICH Q6A, ICH Q3C, and ICH Q3D. Manufacturer lot-specific article codes apply; no compendial model designation has been assigned for this active substance. The salt form is used rather than the free base to improve handling and dissolution; the tosylate content is declared as talazoparib base for labeling. Particle size, polymorphic form, and residual solvent profiles are controlled because these attributes influence the content uniformity of low-dose capsules and the reconstitution behavior of injectable presentations.

Why Is Low-Dose Content Uniformity the Primary Manufacturing Risk for Talazoparib?

Because the clinical dose is only 1 mg once daily and the capsule strength can be 0.25 mg, the principal processing risk is achieving acceptable uniformity of dosage units under USP <905> or Ph. Eur. 2.9.40. Blending of talazoparib tosylate at such low mass fractions requires staged geometric dilution, with each premix step typically maintained at a 1:5 to 1:10 active-to-diluent ratio before integration into a larger carrier blend. Failure to control API particle size and cohesion produces segregation during transfer and compression, leading to acceptance value drift above 15 for 10 dosage units. Batch records from development campaigns therefore specify sieve loading through a 60-mesh screen or equivalent and in-process blend sampling at stratified drum locations. Blend uniformity is assessed by reversed-phase HPLC with a lower limit of quantitation at or below 0.05% of the nominal fill weight; for a 0.25 mg capsule, this corresponds to 0.125 µg per unit. In high-shear mixing, the impeller speed is limited to 10–25 rpm during pre-blend staging to avoid electrostatically driven adhesion to vessel walls. These controls are necessary because talazoparib is effective at microgram-scale systemic exposures and because content uniformity failures cannot be corrected by re-blending once compaction or filling has occurred.

A representative release specification for the tosylate salt includes the following parameters. Limits for impurities and solvents are set from process capability and ICH Q3C options; official pharmacopoeial monographs have not yet been published for talazoparib. The assay method is a validated reversed-phase HPLC procedure with gradient elution and UV detection; the detection wavelength is selected from the compound’s UV spectrum and validated for specificity under forced degradation. Chiral method uses a polysaccharide-based chiral stationary phase; exact conditions are method-specific.

Granule and Tablet Processing Parameters for a Low-Dose Crystalline Tosylate

Direct compression and dry granulation are preferred over aqueous wet granulation for talazoparib tosylate because the low dose does not require wet mass binding and because moisture exposure can be limited to RH ≤ 60% during active blending. Roller compaction with a 0.8 mm screen after milling, followed by final blending with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate, has been evaluated for tablet strengths in development; crushing strength targets of 40–80 N and disintegration times below 15 min in USP <701> are typical for immediate-release formats. Capsule filling on dosator or tamping-pin machines requires powder bed height and fill weight checks at 10–15 min intervals because the low fill weight magnifies density fluctuations. Blend bulk density is commonly controlled between 0.40 g/cm³ and 0.65 g/cm³; flow function coefficients below 4 indicate cohesive behavior and require glidant adjustment. If wet granulation is employed for interparticulate binding, alcohol-based granulating fluid is preferred to water because it reduces exposure of the tosylate salt to high moisture and shortens drying time; the wet mass is dried in a fluid-bed dryer at inlet air temperature not exceeding 60 °C to avoid polymorphic conversion.

For injectable presentations, the tosylate salt must be characterized for pH-solubility from pH 1.2 to 7.4 and for osmolality after pH adjustment. Because talazoparib free base is poorly water-soluble, investigational injectable formulations may require co-solvent systems, cyclodextrin inclusion, or micellar solubilization; published data for this specific configuration is limited. Aseptic processing controls follow EU GMP Annex 1 and 21 CFR 211.113, with terminal sterilization considered only if preformulation data show no degradation. Filtration through 0.22 µm PVDF or PES membranes requires filter integrity testing and extractable/leachable assessment per USP <1663>/USP <1664>. For injectable products, particulate matter must meet USP <788> for subvisible particulates and USP <790> for visible particulates; final sterilization or aseptic filtration requires bacterial retention validation per ASTM F838. If lyophilization is used, collapse temperature and cake appearance are controlled because the low dose may require bulking agents such as mannitol or trehalose to provide a pharmaceutically acceptable cake. Primary packaging includes siliconized glass vials with fluoropolymer-coated stoppers; extractables from the stopper are evaluated according to ICH Q3E.

When Talazoparib Is Compared with Olaparib, Niraparib, and Rucaparib in Solid-Dose Manufacture

The main differentiating parameter is the daily dose. Talazoparib is administered as 1 mg once daily, whereas olaparib is given as 300 mg twice daily, niraparib as 300 mg once daily or 200 mg once daily in selected patients, and rucaparib as 600 mg twice daily. This order-of-magnitude difference drives containment, content uniformity, and analytical sensitivity requirements. Talazoparib also shows higher PARP-trapping potency in published in vitro assays than olaparib at equimolar concentrations; the fold-change varies with assay conditions. Olaparib, niraparib, and rucaparib are formulated as tablets or capsules at higher strengths, which permits direct blending and conventional content uniformity strategies; talazoparib at 0.25 mg per unit cannot tolerate the same dilution without specialized handling. The salt form also differs: talazoparib is supplied as the tosylate salt, similar to niraparib tosylate monohydrate, whereas olaparib is formulated as the free base and rucaparib as the camsylate salt. The salt selection affects aqueous solubility, hygroscopicity, and milling behavior; consequently, process development cannot simply transfer a blending platform from one PARP inhibitor to another.

Stability, Residual Solvent, and Elemental Impurity Control Follow ICH Q1A(R2), Q3C, and Q3D

Forced degradation studies under ICH Q1A(R2) and photostability per ICH Q1B are used to establish stability-indicating HPLC methods. Long-term and intermediate storage conditions are selected according to ICH Q1A(R2); API packaging in double polyethylene bags inside a fiber drum with desiccant is common. Residual solvents are controlled by headspace gas chromatography because the synthesis may include amide coupling and salt-formation solvents; limits are set by ICH Q3C options for Class 1 and Class 2 solvents. Elemental impurities are risk-assessed under ICH Q3D for oral and injectable routes, with palladium and copper typically included if transition-metal catalysis is used. Batch data should be collected over at least three consecutive lots to establish release and stability trends. Stability-indicating parameters include assay, related substances, water content, chiral purity, and powder X-ray diffraction to detect form changes. If the API is micronized, particle size distribution is monitored at release because comminution can produce amorphous content; the amorphous fraction is quantified by modulated differential scanning calorimetry or dynamic vapor sorption at 25 °C and 60% RH. In-use stability for injectable compounding, if applicable, is evaluated under USP <797> for compounded sterile preparations.

For granule production, low-dose talazoparib tosylate can be introduced as a pre-blend with lactose monohydrate or mannitol before roller compaction. The granule size distribution is controlled through 0.5 mm to 1.0 mm milling screens, and residual moisture is held below 2.0% before compression to avoid sticking. In-process controls use loss-on-drying balances and bulk-density cups rather than relying solely on final blend assay, because a 0.25 mg dosage form leaves little room for sampling error. These controls are more demanding than those for the higher-dose PARP inhibitors and define the manufacturing gap between talazoparib and other products in the class.